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Abstract
Background: There is significant interest in new loci for the inherited condition hereditary haemorrhagic
telangiectasia (HHT) because the known disease genes encode proteins involved in vascular transforming growth
factor (TGF)-b signalling pathways, and the disease phenotype appears to be unmasked or provoked by
angiogenesis in man and animal models. In a previous study, we mapped a new locus for HHT (HHT3) to a 5.7 Mb
region of chromosome 5. Some of the polymorphic markers used had been uninformative in key recombinant
individuals, leaving two potentially excludable regions, one of which contained loci for attractive candidate genes
encoding VE Cadherin-2, Sprouty4 and FGF1, proteins involved in angiogenesis.
Methods: Extended analyses in the interval-defining pedigree were performed using informative genomic
sequence variants identified during candidate gene sequencing. These variants were amplified by polymerase
chain reaction; sequenced on an ABI 3730xl, and analysed using FinchTV V1.4.0 software.
Results: Informative genomic sequence variants were used to construct haplotypes permitting more precise citing
of recombination breakpoints. These reduced the uninformative centromeric region from 141.2-144 Mb to between
141.9-142.6 Mb, and the uninformative telomeric region from 145.2-146.9 Mb to between 146.1-146.4 Mb.
Conclusions: The HHT3 interval on chromosome 5 was reduced to 4.5 Mb excluding 30% of the coding genes in
the original HHT3 interval. Strong candidates VE-cadherin-2 and Sprouty4 cannot be HHT3.
Background
Transforming growth factor (TGF)-b superfamily signal-
ling is of fundamental importance to developmental and
physiological regulation. In these pathways (reviewed in
[1,2]), ligands such as TGF-bs, bone morphogenetic pro-
teins (BMP)s, activins, nodals, growth/differentiation fac-
tors (GDF)s and inhibins bind to receptor complexes of
paired type I and type II transmembrane receptor ser-
ine/threonine kinases. Activated type I receptors (ALKs
1-7) phosphorylate receptor-associated Smad proteins in
complex-specific patterns [3-5]. There is increasing
recognition of the role of alternative signalling pathways
for particular ligands within designated cell types. In
endothelial cells (ECs), signalling through the TGF-b
type II receptor, TbRII, can be propagated not only
through ALK-5 via SMAD2/3 as in other cell types, but
also through ALK-1 via SMAD1/5/8, providing two
mutually antagonistic pathways [6,7]. The transmem-
brane glycoprotein endoglin is an accessory TGF-b
receptor, highly expressed on ECs, and is one factor
modulating the balance between ALK-1 and ALK-5
pathways [8].
The inherited vascular condition hereditary haemor-
rhagic telangiectasia (HHT) [9] is of significant relevance
to TGF-b signalling because the genes for endoglin,
ALK-1 and SMAD4 (a co-Smad and downstream effec-
tor of the TGF-b signalling pathway), are mutated in
different HHT families [10-12]. HHT is transmitted as
an autosomal dominant trait due to a single mutation in
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either ENG encoding endoglin (HHT type 1); ACVRL1
encoding ALK-1 (HHT type 2) or SMAD4 (HHT in
association with juvenile polyposis). Perturbation of
TGF-b signalling pathways is therefore implicated in
HHT pathogenesis.
HHT serves not only as a vascular model of aberrant
TGF-b superfamily signalling, but also as a model of
aberrant angiogenesis [13,14]. The abnormal blood ves-
sels develop only in selected vascular beds (telangiectasia
particularly in mucocutaneous and gastrointestinal sites;
arteriovenous malformations (AVMs) most commonly
in pulmonary, hepatic and cerebral circulations) [9,15].
At each site, only a small proportion of vessels are
abnormal. The context in which HHT mutations are
deleterious, when allowing apparently normal endothe-
lial function for most vessels, now appear to be angio-
genic in origin. Early studies modelling HHT in
transgenic animals provided evidence of aberrant angio-
genesis. Heterozygous mice developed HHT-like fea-
tures; Eng and Alk1 null mice died by E11.5 with
normal vasculogenesis but abnormal angiogenesis
[7,16-20]. The zebrafish violet beauregarde (vbg), an
Alk1 mutant, was also homozygous embryonic lethal,
with mutant embryos displaying dilated cranial vessels
attributed to an increased number of endothelial cells
[21]. More recent studies have demonstrated that an
Alk1 deletion in adult mouse subdermal blood vessels
resulted in AVM formation in wounded areas displaying
angiogenesis [22]; that angiogenic stimuli promoted
AVM formation in endothelial specific endoglin knock-
out mice, accompanied by an abnormal increase in EC
proliferation [23] which was also observed in Eng-/-
mouse embryonic ECs [8], and that Alk1 knockout mice
had defective smooth muscle differentiation and recruit-
ment and excessive angiogenesis [7]. These data from
animal models have been accompanied by clinical
reports that Bevacizumab, an antibody against vascular
endothelial growth factor (VEGF)-A, and thalidomide,
appear to have efficacy in treating clinical manifestations
of HHT in man [24,25].
A current model to explain these observations, dis-
cussed in more detail in [26], is based on the EC-mural
cell axis defined by Sato and Rifkin [27]. In angiogenesis,
HHT mutations (endoglin and ALK-1) appear to impair
recruitment of mural cells to the angiogenic sprout
[7,28] at least in part via reduced EC secretion of TGF-
b1 [29,30] and/or reduced TGF-b1 induced responses
[7,29] resulting in defective mural cell stabilisation of
the nascent vessel and persistent, excessive, EC prolif-
eration. Thalidomide, which induced vessel maturation
in Eng+/- mice which normally suffer from excessive
angiogenesis, appears to target mural cell recruitment,
by increasing endothelial expression of PDGF-B at the
endothelial tip cell, thus facilitating recruitment of
pericytes that express PDGFR-b, associated with increas-
ing pericyte proliferation [25].
Further HHT genes were therefore predicted to iden-
tify new components or regulators of TGF-b/BMP sig-
nalling pathways of particular relevance to angiogenesis.
More than 80% of HHT patients carry a sequence varia-
tion in endoglin or ALK-1 [31], most (but not all
[32,33]) disease-causing, whilst 1-2% carry a mutation in
SMAD4 [34]. HHT patients in whom no mutations have
been detected in endoglin, ALK-1 or SMAD4 may have
mutations in unsequenced intronic regions, or unde-
tected large rearrangements of these genes, but impor-
tantly, they may have a mutation in a different gene. A
third gene for pure HHT, HHT3, was mapped in our
laboratory, using the pedigree illustrated in Figure 1A,
to chromosome 5q [35] (Figure 1B), and a fourth,
HHT4, to chromosome 7p [36].
The published chromosome 5 HHT3 interval which
contains the HHT3 gene, is 5.7 Mb long, between
microsatellite markers D5S2011 and D5S2490 (Figure
1B) [35]. This interval contains 38 genes according to
the Ensembl genome browser http://www.ensembl.org.
There were two groups of potentially very attractive
candidate genes. The first encode proteins involved in
angiogenesis: PCDH12 and SPRY4 (discussed further
below), and FGF1 encoding the proangiogenic fibroblast
growth factor 1 [37]). A second group of interval genes
encode proteins involved in signalling by serine/threo-
nine kinases: PPP2R2B which encodes the B regulatory
subunit of protein phosphatase 2A [38], and STK32A,
encoding a serine/threonine kinase [39]. While these
genes had been sequenced with no disease-causing
mutations found ([35], Govani and Shovlin unpub-
lished), this did not exclude the genes as disease-
causing, due to the possibility of undetected intronic
mutations. Importantly PCDH12 (141.3 Mb), SPRY4
(141.6 Mb) and FGF1 (142 Mb) were at the centromeric
extreme of the HHT3 interval, and PPP2R2B (146.4 Mb)
and STK32A (146.6 Mb) at the telomeric extreme, all
within potentially excludable regions of the interval [35].
Excluding any of these genes from the HHT3 interval
was important not only to assist the identification of
HHT3 itself, but also to inform scientists working on
the relevant proteins, particularly VE-Cadherin-2
(encoded by PCDH12) and Sprouty4 (encoded by
SPRY4): VE-Cadherin-2, primarily expressed on ECs
[40], was shown to be down-regulated in HHT1 and
HHT2 blood outgrowth ECs [41] with a role in angio-
genesis [42]. Furthermore, a close family member (VE-
cadherin), associates with endoglin and ALK-1 in cell
surface complexes, and promotes TGF-b1 signalling by
facilitating the recruitment of TGF-b receptor II (TbRII)
into the active signalling complex [43]. Sprouty family
members are involved in branching morphogenesis [44].
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Overexpression of Spry4 in ECs of embryonic day (E)9
mice inhibited angiogenesis [45], whereas surviving
Spry4 knockout mice [46] demonstrated enhanced
angiogenesis [47].
In this study we report the fine mapping of the pub-
lished HHT3 interval using genomic sequence variants
detected during candidate gene sequencing, and exclu-
sion of key genes.
Methods
Pedigree
Ethics approval was obtained from the Multicentre
Research Ethics Committee for Scotland (MREC/98/0/
42; 07/MRE00/19), by the Hammersmith, Queen Char-
lotte’s, Chelsea, and Acton Hospital Research Ethics
Committee (LREC 99/5637M) and in 2007 by the Ham-
mersmith Hospitals Trust (SHOV1022, 2007). The
study is registered on http://www.clinicaltrials.gov
(NCT00230620). The pedigree (Family S, Figure 1A)
and DNA extractions were as described in [35].
PCR and sequencing
Oligonucleotide primers were ordered from Eurofins
MWG-Biotech and amplified in informative members of
Family S by polymerase chain reaction (PCR). Genomic
primers spanning exons and > 30 bp of flanking intronic
sequences were amplified by PCR using Phusion Hot-
start (New England Biolabs) or AmpliTaq Gold (Applied
Biosystems) DNA polymerases. Reactions were per-
formed as recommended by the manufacturers using
35-40 cycles of denaturation, annealing (at primer speci-
fic Ta) and extension. PCR products were treated with
an ExoSAP mix containing SAP enzyme and buffer
(Promega) and ExoI enzyme (New England Biolabs) as
Figure 1 Previous HHT3 interval. A) HHT3 linked Family S pedigree (black symbols represent HHT-affected individuals; white symbols represent
unaffected individuals; squares represent males and circles represent females. Individuals are denoted by their generation number, such that the
oldest male is I.1, oldest female I.2). B) Published HHT3 interval on chromosome 5 between microsatellite markers D5S2011 and D5S2490 [35],
identifying the region shared by all affected individuals (open interval between D5S402 and D5S436); regions where the designated individuals
had inherited their affected parent’s non disease-gene bearing allele (black bars), and regions in which the transition from the non disease-gene
bearing allele (black bars) to disease-gene bearing allele (open interval) had occurred, but the exact sites of the meiotic recombination event
was not definable using the markers studied in [35] (grey bars; uninformative markers). It was possible that the interval could be reduced to a
minimum of D5S402-D5S436, according to where the recombination breakpoints had occurred in individuals II.1, II.3 and II.9. cen: centromere; tel:
telomere; Mb: mega bases.
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previously described [48]; gel purified with Wizard SV
gel and PCR clean-up system (Promega) following the
manufacturer’s protocol; or gel purified and ethanol pre-
cipitated using Costar Spin-X column centrifuge tubes
[49] followed by ethanol precipitation [50]. Purified PCR
products were sequenced in 10 μl reactions with 25 ng
(≅ 3.2 pM) of the sequencing primer on an ABI 3730xl
DNA analyzer (MRC CSC DNA core laboratory, Imper-
ial College London, Hammersmith). The results were
analysed using FinchTV V1.4.0 software (Geospiza, Inc).
Fine mapping
Non-disease causing genomic sequence variants found
during HHT3 candidate gene sequencing were used to
fine map the interval, by providing further polymorph-
isms to track known recombination events through the
uninformative part of the interval. Previously studied
microsatellite polymorphisms had not been able to dis-
tinguish between disease and non-disease alleles (Figure
1B; grey bars), predominantly due to homozygosity in
individual I.2 (Figure 1A). New sequence variants where
individual I.2 was heterozygous (Figure 2) were
sequenced in the interval-defining members of the pedi-
gree (Figure 3). Adjacent genes (such as NR3C1, muta-
tions in which cause glucocorticoid resistance [51]),
were also sequenced to identify further polymorphisms
to define the precise centromeric recombination event.
The alleles inherited by each pedigree member were
then assessed and assigned to maternal or paternal ori-
gin using Mendelian principles. Haplotypes were then
constructed to minimise the number of recombination
events that would be required to generate the segments
of DNA in each offspring. NCBI dbSNP http://www.
ncbi.nlm.nih.gov/projects/SNP/ and SNPbrowser™ V3.5
(Applied Biosystems) were used to determine if the
genomic sequence variants were previously known
(when they were allocated the relevant rs dbSNP
RefSNP label), or novel.
For confirmations of genotypes, SNPs rs153148,
rs34074000, rs164075, rs164077, rs6879694, rs12110022
and rs11958187 were sequenced in two separate PCR
reactions in two or more key individuals.
Genome analysis
Chromosome 5 positions of genomic sequence variants
are based on NCBI Reference build 36 (hg18) assembly.
Results
The HHT3 interval [35] was defined by recombination
events in three affected individuals of Family S, II.1, II.3,
and II.9 (Figure 1). At each end of the interval, there were
regions illustrated by grey bars, in which it was not possible
to state which maternal chromosome 5 allele sequences
these individuals had inherited, due to homozygosity in
individual I.2. New non-microsatellite genomic sequence
variants were identified during candidate gene sequencing
and analysed to assess if they could be used to track the
inheritance of the sequences derived from the two different
alleles of chromosome 5 from individual I.2 in the regions
between D5S2011 and D5S402, and between D5S436 and
D5S2490. A total of 89 genetic sequence variations were
found (75 SNPs, 4 indels and 10 repeats) of which 73 were
present on dbSNP (2010, build 131). Eighteen potentially
informative genomic sequence variants where I.2 was a
heterozygote (seventeen SNPs; one triplet repeat) were
identified within the regions of interest (Figure 2).
Figure 3 tracks the inheritance of alleles at these SNPs
and triplet repeat in the centromeric (Figure 3A), and
telomeric (Figure 3B) extremes of the interval. Although
I.2 shared three genotypes with I.1, it was possible to
definitely state which of I.2’s alleles had been inherited
by each of their children at all sites except rs164077,
rs252108 and rs252109 where genotypes were shared.
Sites where the inheritance of the affected parent’s
alleles could definitely be determined were used to gen-
erate haplotypes.
Figure 2 Informative genomic sequence variants used in fine mapping. Locations of genomic variants where individual I.2 was
heterozygous, potentially allowing her disease associated and non-disease associated alleles to be tracked. Sequence variants are illustrated in
relation to candidate gene exons (grey boxes) and original microsatellite markers. By chance, all five genes are on the reverse strand of
chromosome 5, designated by reverse arrows. rs; as on NCBI dbSNP.
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As shown in Figure 3A, sequencing 15 of these mar-
kers allowed better definition of the centromeric regions
where II.1 and II.3 had inherited the disease-gene asso-
ciated allele, and indicated that the site of the recombi-
nation breakpoint differed in the two individuals. In
individual II.1, the breakpoint had occurred close to
D5S2011 such that he had inherited the maternal dis-
ease allele from rs153148 (within PCDH12) at 141.3 Mb
and onwards. However, in individual II.3, the recombi-
nation event had occurred further into the HHT3 inter-
val: II.3 continued to inherit a different maternal allele
to her affected siblings from rs153148 to a novel SNP
(within FGF1) at 141.9 Mb. By 142.6 Mb (rs17209237
and rs4986593 within NR3C1), II:3 had inherited the
same maternal allele as her affected siblings, siting the
recombination event between 141.9 Mb and 142.6 Mb
(novel SNP and rs17209237)
These data in individual II.3 indicated that in addition
to the definite D5S402-D5S436 region (Figure 1B), the
maximal centromeric extent of the disease gene-bearing
chromosome 5 that could have been inherited by all
affected individuals in the pedigree extended not from
D5S2011 at 141.2 Mb, but from the FGF SNP at 141.9
Mb (Figure 4). This reduction of the uninformative cen-
tromeric region by 0.7 Mb excluded 9 Ensembl interval
genes (Figure 4). PCDH12 and SPRY4 were amongst the
group of genes excluded (Figure 4).
The telomeric border of the HHT3 interval was
defined by a recombination event in affected individual
II.9. This individual had inherited a non-disease allele at
Figure 3 Genomic variant haplotypes in interval-defining members of the pedigree. A) Allele inheritance and haplotypes for the
inheritance of the key microsatellite markers, and new genomic sequence variants, across PCDH12, SPRY4, FGF1 and NR3C1 genes in eight
members of Family S. For each sequence variant, offspring inherit one allele from their mother and one from their father. Occasional alleles
where it was not possible to determine parental origin (and which were therefore not used for haplotype construction) are denoted in non-bold
italics. Individual II.5 demonstrates the disease haplotype across the interval, a haplotype which is now shared by II.1, but not II.3 and her
descendants until rs17209237 in NR3C1. Therefore II.3 excludes the centromeric region between rs153148 and the novel SNP in FGF1. B)
Haplotypes for the inheritance of the new genomic sequence variants across the PPP2R2B gene in nine members of Family S. Affected
individuals II.1, II.3, II.5, III.3 and III.4 demonstrate the disease haplotype which is not shared by II.9 at rs 11958187, but is shared at rs12110022, rs
6879694, and the remainder of the HHT3 interval. Therefore II.9 excludes rs11958187 and beyond from the telomeric extreme of the interval.]:
uninformative regions; bp: base pairs.
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microsatellite markers up to and including D5S2490
(146.9 Mb), and was uninformative at microsatellite
markers up to D5S436 (145.2 Mb) [35] (Figure 1B).
Figure 3B demonstrates the results of sequencing geno-
mic sequence variants within genes in the potentially
excludable telomeric extreme of the interval. II.9 had
inherited the maternal disease allele from rs6879694 to
rs12110022, but a different maternal allele to his
affected siblings at rs11958187 (within PPP2R2B). This
sited the recombination event between 146.1-146.4 Mb,
excluding a further 3 Ensembl interval genes; JAKMIP2,
DPYSL, and STK32A (Figure 4).
Discussion
Identification of further HHT genes is predicted to pro-
vide new insights into TGF-b/BMP signalling and angio-
genesis pathways. The previously published HHT3
interval included several highly attractive candidate
genes. As further evidence accumulated regarding the
roles of particularly VE-cadherin and Sprouty family
members, the possibility that one of these may be
mutated in HHT increased their interest to endothelial
cell biologists. While these genes had been sequenced
with no disease-causing mutations found in the coding
or untranslated regions in affected members of the chro-
mosome 5 linked family ([35], Govani and Shovlin
unpublished), such sequencing did not exclude the
genes as disease-causing, due to the possibility of unde-
tected mutations in intronic or poorly characterised reg-
ulatory regions.
It was recognised that fine mapping of the genomic
variants found during candidate gene sequencing could
help define the critical recombination events and
exclude certain genes, including those for VE-cadherin-2
and Sprouty4. Hence candidate gene sequence variants
were examined in the interval-defining members of the
Figure 4 The refined HHT3 interval. The original HHT3 interval was between microsatellite markers D5S2011 and D5S2490, and uninformative
between D5S2011-D5S402 and D5S2490-D5S436 (black dotted bars) in key individuals II.1, II.3 and II.9 [35]. Informative genomic variations used in
fine mapping reduced the extent of the uninformative regions (grey bars, see Figure 1B). The refined HHT3 interval is sited between a novel SNP
within FGF1 intron 1, and rs11958187 within PPP2R2B intron 4. Black bars indicate the definite recombination events that defined the interval in
the denoted individuals. Fine mapping, by reducing the interval, excluded 12 interval genes as shown in the lower Ensembl genome browser
image of candidate genes (genes no longer in the interval are denoted by orange dotted boxes; Mb: mega bases).
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Family S pedigree that included the crucial individuals
whose recombination events had defined the centro-
meric and telomeric borders of the HHT3 interval.
To optimise PCR fidelity, candidate genes and geno-
mic sequence variants were amplified with AmpliTaq
Gold or Phusion Hotstart DNA polymerases, enzymes
that are inactive until they undergo heat activation to
generate polymerase activity, thus providing an auto-
mated ‘hot start’ [52-54]. To further confirm key geno-
types, SNPs rs153148, rs34074000, rs164075, rs164077,
rs6879694, rs12110022 and rs11958187 were sequenced
in two separate PCR reactions in two or more key
individuals.
Confirmed genotypes allowed construction of haplo-
types across the centromeric and telomeric extremes of
the HHT3 interval. The recombination events were then
sited more precisely, leading to findings which excluded
12 interval genes such as strong candidates PCDH12,
SPRY4 and STK32A. FGF1 and PPP2R2B could not be
fully excluded as the centromeric and telomeric defining
recombination events (SNPs ‘novel’ and rs11958187) are
within the introns of both genes. It should be noted that
the siting of a recombination breakpoint in a single
affected member of the pedigree does not carry any
pathogenic implications for the genes in question, unlike
disease-causing chromosomal rearrangements when the
causative rearrangement is shared by all of the affected
individuals in the pedigree.
The original interval contained 38 genes according to
the Ensembl genome browser. Twelve have been
excluded in this study. The 26 genes that remain include
10 pseudogenes or processed transcripts with no known
protein products; two genes of potential functional rele-
vance to angiogenesis or TGF-b signalling (FGF1 and
PPP2R2B); three protein coding genes associated with
other genetic disease (ARHGAP26; NR3C1 and
POU4F3) and 11 protein coding genes not associated
with a genetic disease but whose gene product had no
obvious function in TGF-b signalling and/or angiogen-
esis (HMHB1; YIPF5; KCTD16; PRELID2; LARS;
TCERG1; SH3RF2; GRXCR2; RBM27; PLAC8L1 and
GPR151).
Conclusions
Further examination of key recombination events in a
known HHT3 pedigree has reduced the published HHT3
gene interval. Crucially, the PCDH12 and SPRY4 genes
were amongst twelve genes no longer in the reduced
interval. Therefore VE-cadherin-2 and Sprouty4, pro-
teins of significant interest to angiogenesis researchers
due to their respective roles in pathophysiological angio-
genesis and relationship to known interactors with the
HHT gene products, are not mutated in HHT3 [55].
Reduction of the interval has facilitated HHT3 gene
identification studies.
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